Literature DB >> 21839835

Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).

Xiaoping Xu1, Margarita Mikhailova, Zhihua Chen, Sanjay Pal, Trista K Robichaud, Eileen M Lafer, Sam Baber, Bjorn Steffensen.   

Abstract

Cellular activation of latent matrix metalloproteinase-2 (proMMP-2) requires formation of a cell membrane-associated activation complex that involves specific binding between the hemopexin domain of proMMP-2 (PEX) and the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (C-TIMP-2). In this study, we tested the feasibility of inhibiting activation of proMMP-2 by exogenous inhibitors, which block the binding between PEX and TIMP-2. The recombinant C-TIMP-2 and synthetic peptides from C-TIMP-2 were used as inhibitors for proMMP-2 activation. Recombinant C-TIMP-2 bound specifically to both the catalytically inactive MMP-2(E404A) and the C-terminal domain of MMP-2 (PEX) in a concentration dependent manner with apparent K(d) of 3.9×10(-7)M and 1.7×10(-7)M, respectively. Moreover, C-TIMP-2 competed the binding between MMP-2(E404A) and full-length TIMP-2. Finally, activity assays showed that addition of C-TIMP-2 to HT-1080 fibrosarcoma cells inhibited proMMP-2 activation in a concentration-dependent manner. We then designed a synthetic peptide, P175L, consisting of 20 residues from the PEX-binding tail region of C-TIMP-2. P175L bound PEX and inhibited cell membrane-mediated activation of proMMP-2 in a concentration dependent manner. Deletion of the last 9 tail residues of C-TIMP-2 in P175L abrogated the inhibitory activities of the peptide showing that these residues were essential for function. Overall, these experiments have demonstrated that proMMP-2 activation can be inhibited by exogenous inhibitors which points to a potential strategy for MMP-2 specific inhibition.
Copyright © 2011 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839835      PMCID: PMC3191288          DOI: 10.1016/j.matbio.2011.07.001

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  43 in total

Review 1.  TIMPs as multifacial proteins.

Authors:  Elise Lambert; Emilie Dassé; Bernard Haye; Emmanuelle Petitfrère
Journal:  Crit Rev Oncol Hematol       Date:  2004-03       Impact factor: 6.312

2.  Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP).

Authors:  R A Williamson; F A Marston; S Angal; P Koklitis; M Panico; H R Morris; A F Carne; B J Smith; T J Harris; R B Freedman
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

3.  Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site.

Authors:  E W Howard; M J Banda
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

4.  Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease.

Authors:  A Y Strongin; I Collier; G Bannikov; B L Marmer; G A Grant; G I Goldberg
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

5.  The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A.

Authors:  F Willenbrock; T Crabbe; P M Slocombe; C W Sutton; A J Docherty; M I Cockett; M O'Shea; K Brocklehurst; I R Phillips; G Murphy
Journal:  Biochemistry       Date:  1993-04-27       Impact factor: 3.162

6.  Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2.

Authors:  A Y Strongin; B L Marmer; G A Grant; G I Goldberg
Journal:  J Biol Chem       Date:  1993-07-05       Impact factor: 5.157

7.  The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity.

Authors:  G Murphy; A Houbrechts; M I Cockett; R A Williamson; M O'Shea; A J Docherty
Journal:  Biochemistry       Date:  1991-08-20       Impact factor: 3.162

Review 8.  Matrix metalloproteases in head and neck cancer.

Authors:  Eben L Rosenthal; Lynn M Matrisian
Journal:  Head Neck       Date:  2006-07       Impact factor: 3.147

9.  Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides.

Authors:  Xiaoping Xu; Yao Wang; Janelle L Lauer-Fields; Gregg B Fields; Bjorn Steffensen
Journal:  Matrix Biol       Date:  2004-06       Impact factor: 11.583

10.  Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2).

Authors:  T Hayakawa; K Yamashita; E Ohuchi; A Shinagawa
Journal:  J Cell Sci       Date:  1994-09       Impact factor: 5.285

View more
  5 in total

1.  The Inhibitory Effect of C-phycocyanin Containing Protein Extract (C-PC Extract) on Human Matrix Metalloproteinases (MMP-2 and MMP-9) in Hepatocellular Cancer Cell Line (HepG2).

Authors:  Mugdha Kunte; Krutika Desai
Journal:  Protein J       Date:  2017-06       Impact factor: 2.371

2.  Selection of peptide inhibitor to matrix metalloproteinase-2 using phage display and its effects on pancreatic cancer cell lines PANC-1 and CFPAC-1.

Authors:  Gao Lu; Maqing Zheng; Yunxia Zhu; Min Sha; Yue Wu; Xiao Han
Journal:  Int J Biol Sci       Date:  2012-05-05       Impact factor: 6.580

3.  Association of SNPs in the TIMP-2 gene and large artery atherosclerotic stroke in southern Chinese Han population.

Authors:  Tie Guo; Haizhen Hao; Lv Zhou; Feng Zhou; Dan Yu
Journal:  Oncotarget       Date:  2017-12-18

Review 4.  Regulation and involvement of matrix metalloproteinases in vascular diseases.

Authors:  Matthew Amin; Sathnur Pushpakumar; Nino Muradashvili; Sourav Kundu; Suresh C Tyagi; Utpal Sen
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01-01

5.  Beyond the limits of oxygen: effects of hypoxia in a hormone-independent prostate cancer cell line.

Authors:  A C Mamede; A M Abrantes; L Pedrosa; J E Casalta-Lopes; A S Pires; R J Teixo; A C Gonçalves; A B Sarmento-Ribeiro; C J Maia; M F Botelho
Journal:  ISRN Oncol       Date:  2013-09-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.